Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients Investor Brand Network - Wed Oct 30, 11:14AM CDT

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging...

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies Investor Brand Network - Thu Oct 24, 9:07AM CDT

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s...

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) to Present Alzheimer’s Research at CTAD Conference in Madrid Investor Brand Network - Wed Oct 23, 9:20AM CDT

Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid...

ANVS : 8.73 (-3.96%)
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 GlobeNewswire - Tue Oct 22, 7:00AM CDT

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial Investor Brand Network - Wed Oct 16, 9:43AM CDT

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.73 (-3.96%)
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs GlobeNewswire - Tue Oct 15, 7:00AM CDT

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio Investor Brand Network - Mon Oct 7, 9:58AM CDT

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.73 (-3.96%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More Investor Brand Network - Fri Oct 4, 10:35AM CDT

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address...

ANVS : 8.73 (-3.96%)
JNJ : 158.24 (-1.18%)
MRK : 101.87 (-0.01%)
NVS : 110.52 (+1.07%)
GSK : 36.97 (+0.24%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More FinancialNewsMedia - Thu Oct 3, 7:30AM CDT

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

ANVS : 8.73 (-3.96%)
JNJ : 158.24 (-1.18%)
MRK : 101.87 (-0.01%)
NVS : 110.52 (+1.07%)
GSK : 36.97 (+0.24%)
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases GlobeNewswire - Thu Oct 3, 7:30AM CDT

ANVS : 8.73 (-3.96%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings? Barchart - 1 hour ago
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot